8-KAccepted Nov 16, 7:17 AM ET
Larimar Therapeutics, Inc.: reports Q3 2026 results
Accepted (ET)
7:17 AM
Nov 16, 2026
Filed
Nov 16, 2026
Documents
12
Size
1.1 MB
Summary
Larimar Therapeutics, Inc.: reports Q3 2026 results
What happened
- The filing says: On Nov 16, 2026, Larimar Therapeutics, Inc. announced its financial results and operational highlights for the third quarter ended Sep 30, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
- The report is signed by Carole S. Ben-Maimon, M.D., Chief Executive Officer, dated Nov 16, 2026.
Key details
- Item 2.02 reported results of operations and financial condition for the quarter ended Sep 30, 2026.
- Exhibit 99.1 is the press release issued by Larimar Therapeutics, Inc. on Nov 16, 2026 and is furnished with the report.
- Exhibit 104 is the cover page interactive data file embedded within the Inline XBRL document.
- The Current Report on Form 8-K is dated Nov 16, 2026 and was signed by the CEO, Carole S. Ben-Maimon, M.D.
Why it may matter
- Item 2.02 covers the company's results of operations and financial condition; Item 9.01 lists exhibits filed or furnished with the report, including the press release and the interactive XBRL cover page.
- This filing does not show why the insider traded or why the company acted.